Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 6,268,579 shares, a decline of 12.6% from the October 31st total of 7,176,264 shares. Approximately 5.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 909,188 shares, the short-interest ratio is presently 6.9 days.
Shares of Synthetic Biologics (SYN) opened at $0.51 on Wednesday. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.05.
Synthetic Biologics (NYSEAMERICAN:SYN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.10).
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.